Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-2741a first-in-human phase 1 study in healthy volunteers and patients with atopic dermatitis
jRCT2080224983Phase 1Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of DS-2741a in atopic dermatitis (AD) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety, Pharmacokinetics and 2 more. Started Dec 2019; status: terminated.
02
Drugs
DS-2741a
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080224983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224983.